PanGen Biotech Inc (222110) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.122x

Based on the latest financial reports, PanGen Biotech Inc (222110) has a cash flow conversion efficiency ratio of -0.122x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.66 Billion ≈ $-2.48 Million USD) by net assets (₩30.03 Billion ≈ $20.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

PanGen Biotech Inc - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how PanGen Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PanGen Biotech Inc balance sheet liabilities for a breakdown of total debt and financial obligations.

PanGen Biotech Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PanGen Biotech Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Duran-Dogan Basim ve Ambalaj Sanayi AS
IS:DURDO
0.120x
Sanica Isi Sanayi A.S.
IS:SNICA
-0.015x
AC S.A.
WAR:ACG
0.075x
Bai Sha Technology Co Ltd
TWO:8401
0.046x
Herantis Pharma Oyj
HE:HRTIS
-1.937x
REDCO PRP GROUP LTD -05
F:8KI
N/A
Finetechnix. Co.Ltd
KQ:106240
0.015x
MCE Holdings Bhd
KLSE:7004
0.008x

Annual Cash Flow Conversion Efficiency for PanGen Biotech Inc (2014–2024)

The table below shows the annual cash flow conversion efficiency of PanGen Biotech Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see PanGen Biotech Inc market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩24.91 Billion
≈ $16.88 Million
₩2.99 Billion
≈ $2.02 Million
0.120x +143.67%
2023-12-31 ₩12.57 Billion
≈ $8.52 Million
₩-3.45 Billion
≈ $-2.34 Million
-0.275x -35.00%
2022-12-31 ₩17.22 Billion
≈ $11.67 Million
₩-3.50 Billion
≈ $-2.37 Million
-0.203x -29.11%
2021-12-31 ₩21.10 Billion
≈ $14.30 Million
₩-3.32 Billion
≈ $-2.25 Million
-0.158x +52.17%
2020-12-31 ₩14.21 Billion
≈ $9.63 Million
₩-4.68 Billion
≈ $-3.17 Million
-0.329x -65.73%
2019-12-31 ₩18.43 Billion
≈ $12.49 Million
₩-3.66 Billion
≈ $-2.48 Million
-0.199x +4.56%
2018-12-31 ₩26.94 Billion
≈ $18.26 Million
₩-5.61 Billion
≈ $-3.80 Million
-0.208x -891.15%
2017-12-31 ₩31.31 Billion
≈ $21.22 Million
₩-657.84 Million
≈ $-445.81K
-0.021x +82.93%
2016-12-31 ₩35.31 Billion
≈ $23.93 Million
₩-4.35 Billion
≈ $-2.94 Million
-0.123x +49.74%
2015-12-31 ₩6.56 Billion
≈ $4.45 Million
₩-1.61 Billion
≈ $-1.09 Million
-0.245x -95.31%
2014-12-31 ₩10.69 Billion
≈ $7.24 Million
₩-1.34 Billion
≈ $-908.12K
-0.125x --

About PanGen Biotech Inc

KQ:222110 Korea Biotechnology
Market Cap
$54.41 Million
₩80.29 Billion KRW
Market Cap Rank
#21565 Global
#1392 in Korea
Share Price
₩5950.00
Change (1 day)
-0.83%
52-Week Range
₩4555.00 - ₩7340.00
All Time High
₩24450.00
About

PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, … Read more